AKBLF.US ALK-Abelló A/S

Healthcare Biotechnology USA Stocks
40.17 USD
Close of Nov 14, 2026
30.50 40.65
Market cap
USD 8.10B
P/E
38.4x
P/B
7.81x
ROE
22.4%
Dividend yield
0.67%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AKBLF.US undervalued?

Graham number

The Graham number of ALK-Abelló A/S cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALK-Abelló A/S fundamental analysis

No fundamental analysis for ALK-Abelló A/S yet.

ALK-Abelló A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALK-Abelló A/S

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ra…

Full company profile